Schoedel, K.; Heim, T.; Duensing, A.; Lohse, I.; Presutti, L.; Belayneh, R.; Bhogal, S.; Singh-Varma, A.; Chang, A.; Chandran, U.;
et al. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy. Cancers 2024, 16, 247.
https://doi.org/10.3390/cancers16020247
AMA Style
Schoedel K, Heim T, Duensing A, Lohse I, Presutti L, Belayneh R, Bhogal S, Singh-Varma A, Chang A, Chandran U,
et al. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy. Cancers. 2024; 16(2):247.
https://doi.org/10.3390/cancers16020247
Chicago/Turabian Style
Schoedel, Karen, Tanya Heim, Anette Duensing, Ines Lohse, Laura Presutti, Rebekah Belayneh, Sumail Bhogal, Anya Singh-Varma, Alexander Chang, Uma Chandran,
and et al. 2024. "Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy" Cancers 16, no. 2: 247.
https://doi.org/10.3390/cancers16020247
APA Style
Schoedel, K., Heim, T., Duensing, A., Lohse, I., Presutti, L., Belayneh, R., Bhogal, S., Singh-Varma, A., Chang, A., Chandran, U., Marker, D., Szabo-Rogers, H., & Weiss, K.
(2024). Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy. Cancers, 16(2), 247.
https://doi.org/10.3390/cancers16020247
